Neostem Inc (NASDAQ:NBS)

CAPS Rating: 3 out of 5

Results 1 - 20 of 32 : 1 2 Next »

Recs

0
Member Avatar TerryHoodSr (49.05) Submitted: 4/15/2014 9:52:51 AM : Outperform Start Price: $6.86 NBS Score: -4.29

trade buy@ 6.8 TP 8

Recs

0
Member Avatar TerryFool (< 20) Submitted: 4/4/2014 3:50:58 PM : Outperform Start Price: $6.97 NBS Score: -4.20

BUY PULLBACK

Recs

0
Member Avatar gunterle (65.33) Submitted: 3/11/2014 2:00:15 PM : Outperform Start Price: $7.57 NBS Score: -11.43

signal

Recs

0
Member Avatar lewis33 (< 20) Submitted: 1/31/2014 2:10:48 PM : Outperform Start Price: $7.32 NBS Score: -13.05

stem cell research is wave of the future. the future is now!

Recs

0
Member Avatar TempoAllegro (46.66) Submitted: 1/30/2014 10:08:21 AM : Outperform Start Price: $7.03 NBS Score: -10.79

NBS has a novel therapy using stem cells that may become the standard of the cardio-health industry. This is a small company with lots of potential and multiple irons in the fire.

Recs

0
Member Avatar tjpliss (< 20) Submitted: 12/13/2013 7:43:38 AM : Outperform Start Price: $6.06 NBS Score: +5.63

i think in time

Recs

0
Member Avatar KattyKay (84.40) Submitted: 11/17/2013 11:25:12 AM : Outperform Start Price: $6.34 NBS Score: +1.85

NBS has 4 business units- each of which could easily be a company in its own right. They are at the forefront of a new paradigm in treating certain diseases. The current money-maker is Progenitor Cell Therapy (PCT) which is the manufacturing unit using proprietary technology to manufacture stem cells for other pharma companies. This allows NBS to make money while developing their own stem cell therapies. And perfect their manufacturing techniques. The best known unit is Amorcyte due to phase 2 clinical trial of AMR-001 (autologous marrow stem cells f) for acute myocardial infarction. The Athelos unit is developing the lesser know human regulatory T cell therapy approach (patented technology) to immune-mediated diseases (ie, asthma or type 1 diabetes). This Treg technology has been licensed out to other companies, earning money for the development of this novel therapeutic approach. The VSEL unit is developing pluripotent stem cells (very small embryonic-like stem cells) for regenerative therapies (e.g., wounds or bone regeneration). As this is early research, VSEL is partnering with universities and government organizations to learn about these VSELs. Finally, tthrough the relationships with pharma companies developed by PCT or Athelos, NBS could potentially negotiate a favorable development agreement with a larger company to fund clinical development through phase 3 and approval. This approach has worked for other small biotech companies in recent years. As a forerunner in this new field, NBS could bring one of the first 'stem cell' therapies to market in the next 3 to 5 years.

Recs

1
Member Avatar kattazei (58.12) Submitted: 7/9/2013 9:17:33 PM : Outperform Start Price: $5.80 NBS Score: +2.00

It will take some more time to start moving up but it will happen.

Recs

0
Member Avatar Raultest1 (< 20) Submitted: 6/21/2013 8:03:58 PM : Outperform Start Price: $5.27 NBS Score: +8.13

I think it's a well managed company and should out perform the market.

Recs

0
Member Avatar topsav1 (< 20) Submitted: 6/18/2013 2:41:55 PM : Outperform Start Price: $5.25 NBS Score: +14.67

New cardiac technologies to take off

Recs

0
Member Avatar topsav (< 20) Submitted: 5/15/2013 12:20:40 PM : Outperform Start Price: $5.95 NBS Score: -0.09

upcoming technologies

Recs

0
Member Avatar neoexmnist (68.48) Submitted: 12/18/2012 7:33:14 AM : Outperform Start Price: $6.50 NBS Score: -26.79

NeoStem is projected to have their first treatment commercialized in 2017.

Recs

0
Member Avatar Brilliantdummy (61.00) Submitted: 10/29/2012 12:22:31 PM : Outperform Start Price: $6.60 NBS Score: -30.30

Allah peanut butter sandwiches;)~

Recs

0
Member Avatar adzturbot (53.82) Submitted: 10/23/2012 10:32:08 PM : Outperform Start Price: $7.25 NBS Score: -39.28

rock solid on the current market pullback. Watch this fly once it gets the chance

Recs

1
Member Avatar Pharmagirl (< 20) Submitted: 9/11/2012 11:21:26 PM : Outperform Start Price: $6.70 NBS Score: -29.50

Most of the medical profession, maybe not Wall Street, recognizes we've entered a new age in cancer and cardiac care. Thanks to stem cell and genetics research, we're moving from cutting to perhaps curing, or in the very least, offering patients less invasive procedures that may very well help extend their lives.

Recs

0
Member Avatar ThinkBullish (< 20) Submitted: 7/30/2012 11:40:31 AM : Outperform Start Price: $6.85 NBS Score: -35.42

Highly undervalued considering the amount of potential it has. I'm not religious but you can't bet against a company backed by the Pope either :)

Recs

0
Member Avatar GirlsUnder30 (96.31) Submitted: 7/28/2012 10:46:20 AM : Outperform Start Price: $7.09 NBS Score: -40.17

I'm in NY and I know this company. Expect some future stock dilution or debt issues if it stays independent but I expect it will be acquired at some point.

Recs

0
Member Avatar SamsaricSufferer (< 20) Submitted: 7/4/2012 8:14:51 PM : Outperform Start Price: $5.75 NBS Score: -20.13

Stem cell expertise.

Recs

1
Member Avatar valueseeker1 (86.94) Submitted: 1/20/2012 9:43:34 AM : Outperform Start Price: $7.40 NBS Score: -51.87

This is a high risk / high reward extreme speculation, on my part.
This is based on current momentum.

Recs

0
Member Avatar Imhilion (93.61) Submitted: 1/11/2012 2:04:52 PM : Outperform Start Price: $5.10 NBS Score: -14.00

Should've put this at five years, long term stem cell research play

Results 1 - 20 of 32 : 1 2 Next »

Featured Broker Partners


Advertisement